[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643890":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":43,"id":58,"slug":10,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":78,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Glofitamab + Selinexor Cohort",null,"Patients with relapsed or refractory diffuse large B-cell lymphoma (R\u002FR DLBCL) receiving up to 12 cycles of glofitamab in combination with selinexor.",[13],"Drug: Glofitamab combined with selinexor",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Glofitamab combined with selinexor","Patients receive obinutuzumab 1000 mg intravenously (IV) on Day 1 of Cycle 1 to mitigate cytokine release syndrome (CRS) risk. Glofitamab is administered IV with step-up dosing at 2.5 mg on Day 8 and 10 mg on Day 15 of Cycle 1, followed by a target dose of 30 mg on Day 1 of Cycles 2 through 12. Selinexor is administered orally at 60 mg on Days 1 and 3 of each week, starting from Cycle 2 through Cycle 12. Each cycle is 21 days. The total fixed duration of treatment is 12 cycles.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Jiefeng Tong","CONTACT","13588710821","jeffytong@163.com",[27],{"facility":5,"status":10,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Hangzhou","Zhejiang","310009","China","CN",{"type":34,"coordinates":35},"Point",[36,37],120.16142,30.29365,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":42,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[44,46,48,50,52,54,56],{"name":45,"class":6},"Zhejiang Provincial People's Hospital",{"name":47,"class":6},"The First Affiliated Hospital of Zhejiang Chinese Medical University",{"name":49,"class":6},"Zhejiang Provincial Tongde Hospital",{"name":51,"class":6},"Affiliated Hospital of Jiaxing University",{"name":53,"class":6},"Shaoxing People's Hospital",{"name":55,"class":6},"Shaoxing Central Hospital",{"name":57,"class":6},"Zhuji People's Hospital of Zhejiang Province","100643890",false,"NCT07669194","Glofitamab Combined With Selinexor in Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","Observational Real-World Study of Glofitamab Combined With Selinexor for Patients With Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma (R\u002FR DLBCL)","Glofit-Sel","Inclusion Criteria:\n\n* Age 18 years and older at the time of informed consent.\n* Histologically confirmed CD20+ diffuse large B-cell lymphoma (DLBCL).\n* Relapsed or refractory disease, having previously received at least two lines of systemic therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.\n* Presence of measurable disease.\n* Adequate hematologic, hepatic, and renal function.\n* Willingness to use effective contraception methods during the study and for a specified period after the last dose.\n* Willing and able to provide written informed consent and comply with the study protocol.\n\nExclusion Criteria:\n\n* Prior treatment with any CD20\u002FCD3 bispecific antibodies or XPO1 inhibitors.\n* Current or prior history of central nervous system (CNS) involvement by lymphoma or other significant CNS diseases.\n* Active and uncontrolled systemic infections, including known HIV infection, active Hepatitis B virus (HBV), or active Hepatitis C virus (HCV) infection.\n* Active autoimmune diseases requiring systemic immunosuppressive therapy.\n* Clinically significant, severe, or uncontrolled cardiovascular diseases.\n* Other active invasive malignancies within the past 2 years (with exceptions for adequately treated localized cancers).\n* Recent major surgery or receipt of live attenuated vaccines within a specified timeframe prior to the study.\n* Severe gastrointestinal conditions that may significantly affect the absorption of oral medications.\n* Known severe allergic reactions to any of the study drugs or their excipients.\n* Pregnant or breastfeeding women.","ALL","18 Years",{"count":68,"type":69},30,"ESTIMATED","OBSERVATIONAL","Assess the efficacy and safety of glofitamab in combination with selinexor for the treatment of relapsed or refractory diffuse large B-cell lymphoma (R\u002FR DLBCL) in patients who have received at least two prior lines of systemic therapy.",[73],"Diffuse Large B-Cell Lymphoma (DLBCL)",[75,76,77],"Relapsed\u002FRefractory","Glofitamab","Selinexor","NOT_YET_RECRUITING","2026-06-22",{"date":81,"type":82},"2026-06-25","ACTUAL",{"date":84,"type":69},"2026-06-10",{"date":86,"type":69},"2029-04-30",{"name":5,"class":6},1]